spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Novartis Pharmaceuticals 

 HSMN NewsFeed - 12 Jan 2023
Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jun 2022
INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Apr 2022
FDA approves Novartis Vijoice(R) (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Mar 2022
Orna Therapeutics Bolsters Leadership Team with Key Executive and Board Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jun 2021
Valeo Pharma Announces Commercial Launch of Enerzair(R) Breezhaler(R) and Atectura(R) Breezhaler(R)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 1 Dec 2020
Novartis announces FDA approval of Xolair(R) (omalizumab) for adults with nasal polyps
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Oct 2020
Dewpoint Therapeutics Appoints Ameet Nathwani as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 31 Mar 2020
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Feb 2020
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jul 2019
Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Jun 2019
Castle Creek Pharmaceuticals Appoints Mary Spellman, M.D., as Chief Medical Officer and Senior Vice President of Research & Development
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 25 Apr 2019
DURECT Appoints Two New Board Members
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 27 Mar 2019
Novartis receives FDA approval for Mayzent(R) (siponimod), the first oral drug to treat secondary progressive MS with active disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 21 Feb 2019
Denovo Biopharma Announces New Hires for Positions of Chief Medical Officer of Hematology and Senior Vice President, Regulatory Affairs and Quality Assurance
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Jan 2019
Altavant Sciences Appoints Lyn Baranowski Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jul 2018
Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 May 2018
FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
Biopharmaceuticals Devices Drug Delivery FDA
 HSMN NewsFeed - 10 May 2018
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 25 Apr 2018
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
Biopharmaceuticals Ophthalmology Product Launch
 HSMN NewsFeed - 19 Mar 2018
PMV Pharma Appoints Salim Yazji, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jan 2018
Novartis new data reinforces superiority of Cosentyx(R) versus Stelara(R) in achieving skin clearance for psoriasis patients
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Jan 2018
Novartis drug Promacta(R) receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Dec 2017
Novartis' combination therapy Tafinlar(R) + Mekinist(R) granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 Jul 2017
Evelo Biosciences Announces $50 Million Series B Financing and Expansion of Board and Leadership Team
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Apr 2017
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Apr 2017
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Feb 2017
Sangamo Therapeutics Announces Chief Financial Officer Succession
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 17 Feb 2017
AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2016
Aclaris Therapeutics, Inc. Appoints Kevin Scott as Vice President of Sales
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jan 2016
Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Nov 2015
Seres Therapeutics Appoints Kurt Graves to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Aug 2015
Chiasma Appoints William H. Ludlam, M.D., Ph.D., as Vice President of Medical Affairs
Biopharmaceuticals Endocrinology Personnel
 HSMN NewsFeed - 24 Jul 2015
FDA approves Novartis drug Odomzo(R) (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Jul 2015
Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Apr 2015
Akorn Announces Recent Executive Appointments
Biopharmaceuticals Generic Personnel
 HSMN NewsFeed - 17 Dec 2014
Bovie Medical Corporation Further Expands Its Direct Sales Force
Devices Personnel
 HSMN NewsFeed - 16 Dec 2014
Novartis gains FDA approval for Signifor(R) LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Oct 2014
Otonomy Appoints Anthony J. Yost Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 May 2014
Charleston Laboratories, Inc., Bolsters Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 May 2014
Timothy Maloney appointed President of Novartis Pharmaceuticals Canada Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Mar 2014
Baxter Announces Plans to Create Two Separate Leading Global Healthcare Companies
Biopharmaceuticals Devices Personnel
 HSMN NewsFeed - 19 Feb 2014
Ignyta Appoints Sara Zaknoen, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Oct 2013
Mallinckrodt Pharmaceuticals Announces Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Oct 2013
Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Oct 2013
Sideris Pharmaceuticals Completes $32 Million Equity Financing and Signs Agreement With Global Pharmaceutical Company
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 11 Oct 2013
Syndax Names Steven M. Fruchtman, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Oct 2013
FDA Files Genentech’s Supplemental Biologics License Application of Xolair(R) (omalizumab) for Chronic Idiopathic Urticaria (CIU)
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 8 Oct 2013
MolecularHealth Continues to Grow Management Team with New Chief Commercial Officer
Diagnostics Personalized Medicine Oncology Personnel
 HSMN NewsFeed - 21 Aug 2013
Ironwood Pharmaceuticals Appoints Dr. Michael Hall as Senior Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Aug 2013
Enteris BioPharma Appoints Timothy J. Saxon, Vice President of Business Development, to Expand "Peptelligence(TM) Partnering" Program
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA
 HSMN NewsFeed - 18 Dec 2012
Blend Therapeutics Appoints Mark Iwicki as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Nov 2012
Validus Pharmaceuticals Now Exclusively Marketing Six Established U.S. Product Lines Purchased From Leading Healthcare Company
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 4 Sep 2012
Higher dose of Novartis drug Exelon(R) Patch approved by FDA for patients with mild to moderate Alzheimer's disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 26 Jul 2012
Endocyte Appoints David Meek to Newly Created Position of Chief Commercial Officer
Biopharmaceuticals Personalized Medicine Personnel
 HSMN NewsFeed - 16 Apr 2012
Insmed Announces First Patient Dosed in Pivotal European Phase 3 Clinical Study of ARIKACE(R) in Cystic Fibrosis Patients with Pseudomonas Lung Infections
Biopharmaceuticals
 HSMN NewsFeed - 3 Feb 2012
Prometheus Announces New Chief Commercial Officer
Diagnostics Personnel
 HSMN NewsFeed - 1 Feb 2012
FDA approves Novartis drug Gleevec(R) label recommending extending treatment to three years for certain GIST patients after surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Nov 2011
Mylan Announces Settlement Agreement for its First-to-File Generic Version of Vivelle-Dot(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 15 Sep 2011
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Aug 2011
Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2011
HealOr Names Dr. Michael L. Sabolinski, M.D. as New CEO
Biopharmaceuticals Wound Care Personnel
 HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2011
Blueprint Medicines Secures $40 Million Series A Financing to Translate New Molecular Data into Personalized Cancer Treatments
Personalized Medicine Oncology Venture Capital
 HSMN NewsFeed - 11 Apr 2011
Novartis Therapy Gilenya Reduced the Risk of MS Disability Progression Regardless of Treatment History or Disease Severity, New Analysis Shows
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Dec 2010
Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee
Biopharmaceuticals Devices Personnel
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Nov 2010
FDA Approves Movement Disorder Drug from CNS Therapeutics: Gablofen(R) (Baclofen Injection) for the Treatment of Severe Spasticity
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 3 Nov 2010
Study in NEJM Shows Novartis Drug Afinitor(R) Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2010
Novartis Drug Afinitor(R) Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 15 Oct 2010
Watson's Generic Version of Lotrel(R) Receives FDA Approval
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 11 Oct 2010
Phase III Novartis Data Show Potential Benefit of Afinitor(R) Plus Sandostatin(R) LAR Depot in Patients with Advanced Carcinoid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2010
Novartis gains FDA approval for Gilenya, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Sep 2010
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Biopharmaceuticals
 HSMN NewsFeed - 27 Aug 2010
Novartis receives FDA approval of Tekamlo, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2010
Pivotal Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2010
Novartis Receives US FDA Approval for Zortress(R) (everolimus) to Prevent Organ Rejection in Adult Kidney Transplant Recipients
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Feb 2010
Acorda Therapeutics Announces Adrian L. Rabinowicz Joins as Senior Vice President of Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Feb 2010
Lantheus Medical Imaging, Inc. Announces Appointment of Robert A. Spurr as Vice President, Sales and Marketing
Biopharmaceuticals Radiology Personnel
 HSMN NewsFeed - 8 Feb 2010
Lupin Receives FDA Approval for Amlodipine/Benazepril Capsules
Biopharmaceuticals FDA Generics
 HSMN NewsFeed - 18 Jan 2010
T-Ray Science, Inc. Announces Changes in Management
Devices Oncology Personnel
 HSMN NewsFeed - 11 Jan 2010
Novartis Launches Schizophrenia Treatment Fanapt in the US, Offering Patients an Attractive Alternative to Existing Medications
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2010
Acetylon Pharmaceuticals Tops Up Series A Financing with $2 Million Note And Appoints Simon Jones VP Biology and Preclinical Development and John van Duzer VP Chemistry and Manufacturing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 4 Jan 2010
Noven Announces New Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Oct 2009
Transdel Pharmaceuticals Appoints Dr. Joachim P.H. Schupp as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Oct 2009
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 19 Aug 2009
Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Biopharmaceuticals Onology
 HSMN NewsFeed - 21 Jul 2009
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jun 2009
Paulo F. Costa Joins MacroGenics Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2009
FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Mar 2009
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jan 2009
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge in France
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2009
Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jan 2009
Valeant Pharmaceuticals Appoints Chief Operating Officer of Specialty Pharmaceuticals
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 2 Dec 2008
Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
Biopharmaceuticals Generics Oncology
 HSMN NewsFeed - 22 Sep 2008
Molecular Insight Pharmaceuticals, Inc. Adds Four Healthcare Industry Experts to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Aug 2008
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jul 2008
Isis Announces Appointment of Martin P. Bedigian, M.D. as Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2008
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2008
Noven Names Anthony Venditti Vice President - Marketing & Sales
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jun 2008
FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 May 2008
Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 May 2008
XenoPort Appoints Vincent J. Angotti as Chief Commercialization Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Apr 2008
Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2008
PDI Signs Promotion Agreement with Major Pharmaceutical Company
Biopharmaceuticals
 HSMN NewsFeed - 31 Mar 2008
Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 10 Mar 2008
Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Feb 2008
ImmunoCellular Therapeutics Announces New President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Feb 2008
Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jan 2008
Breckenridge Pharmaceutical Settles 'Paragraph IV' Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 8 Jan 2008
Callisto Pharmaceuticals Announces Investor Conference Call to Provide Details on Guanilib Strategic Initiative in GI Disorders
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 3 Jan 2008
Noven Announces Changes to Board of Directors and Senior Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Dec 2007
Manhattan Pharmaceuticals Names Mary C. Spellman, M.D. as Head of Dermatology and Drug Development
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 20 Dec 2007
Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2007
Once-Daily Exjade(R) Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2007
Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 3 Dec 2007
FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Nov 2007
Achillion Announces Appointment of New Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Nov 2007
Barr Confirms Patent Challenge of Focalin(R) XR
Biopharmaceuticals Generics
 HSMN NewsFeed - 18 Oct 2007
Duska Therapeutics Appoints Shepard Goldberg and Steven Dinh as Board Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Oct 2007
EntreMed Appoints Senior Vice President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2007
Callisto Pharmaceuticals Announces Major Strategic Initiative for Guanilib in GI Disorders
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 Sep 2007
First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2007
Infinity and MedImmune Receive Orphan Drug Designation for IPI-504 for Treatment of Gastroinstestinal Stromal Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Sep 2007
New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
Biopharmaceuticals
 HSMN NewsFeed - 11 Sep 2007
NCCN Updates Dermatofibrosarcoma Protuberans Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Aug 2007
Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Aug 2007
FDA Grants Additional Six Months Marketing Exclusivity for the High Blood Pressure Medicine Diovan(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Jul 2007
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Jun 2007
Vertex Pharmaceuticals Announces Two Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jun 2007
Critical Therapeutics and Dey, L.P. Complete Definitive Co-Promotion Agreement for Perforomist(TM) Inhalation Solution
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 21 Jun 2007
LifeCycle Pharma Forms Scientific Advisory Board in Solid Organ Transplantation
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jun 2007
Exforge(R) Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Jun 2007
INNOVIVE Pharmaceuticals Presents Additional Phase I Data on INNO-406 for Treatment of Gleevec-Resistant or Intolerant Chronic Myelogenous Leukemia at the American Society of Clinical Oncology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2007
Talima Therapeutics Secures $19 Million Series B
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 21 May 2007
Single-Tablet Combination of Tekturna(R) and Diuretic, an Important New Option for People With High Blood Pressure, Accepted for Review in U.S.
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 May 2007
Mylan Announces Tentative FDA Approval for Letrozole Tablets, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 2 May 2007
Once-yearly Reclast(R) Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis
Biopharmaceuticals Orthopaedic
 HSMN NewsFeed - 26 Apr 2007
Study Supports Cost-Effectiveness of Medtronic's Spasticity Treatment for Children with Cerebral Palsy
Devices Neurology
 HSMN NewsFeed - 17 Apr 2007
Reclast(R) Receives US Approval as a Highly Effective Treatment for Patients with Paget's Disease of the Bone
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Apr 2007
Positive Results Prompt US National Cancer Institute to Make Gleevec(R) Available To Patients in Post-Surgical GIST Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Apr 2007
Amarin Appoints Paul F. Duffy to New Position of President - U.S. Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Mar 2007
Novartis Suspends US Marketing and Sales of Zelnorm(R) in Response to Request from FDA
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 26 Mar 2007
Tekturna(R), First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Mar 2007
Tekturna(R) - The First New Type of High Blood Pressure Medicine In More Than a Decade - Receives Its First Approval in the US
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 26 Feb 2007
Lexicon Announces Executive Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2007
Bausch & Lomb Announces Changes in Americas Region Commercial Management
Devices Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 4 Jan 2007
INNOVIVE Pharmaceuticals Announces Receipt of FDA Orphan Drug Designation for INNO-406 for the Treatment of Chronic Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Dec 2006
Savient Pharmaceuticals Announces Launch of Authorized Generic of Oxandrin(R) with Watson Pharmaceuticals
Biopharmaceuticals Generics
 HSMN NewsFeed - 13 Dec 2006
Ambit Biosciences Announces Establishment of Clinical Oncology Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Dec 2006
Savient Pharmaceuticals Announces Appellate Court Decision in Patent Infringement Lawsuit against Sandoz Pharmaceuticals and Upsher-Smith Laboratories
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 12 Dec 2006
INNOVIVE Pharmaceuticals Presents Data on Oncology Drug Programs in Chronic Myelogenous Leukemia and Acute Myelogenous Leukemia at American Society of Hematology 48th Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2006
Endo Pharmaceuticals Appoints Charles Rowland as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2006
New Evidence Reinforces Efficacy and Tolerability of Galvus(R) as a New Once-Daily Oral Treatment Option for Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 5 Dec 2006
Savient Pharmaceuticals Obtains Temporary Restraining Order in Patent Infringement Lawsuit Against Sandoz Pharmaceuticals and Upsher-Smith Laboratories
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 4 Dec 2006
Savient Pharmaceuticals Files Patent Infringement Lawsuit Against Sandoz Pharmaceuticals and Upsher-Smith Laboratories
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 21 Nov 2006
Celtic Pharma Appoints Two New Senior Executives
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Nov 2006
Ambrilia Announces European Licensing Partnership with TEVA for its Lead Oncology Product, Octreotide
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Nov 2006
Stroke Survivors Benefit Significantly from Targeted Spasticity Treatment Using Medtronic Drug Pump, Study Finds
Devices Neurology Drug Delivery
 HSMN NewsFeed - 31 Oct 2006
Boston Scientific Appoints Steven L. Zelenkofske Patient Safety Officer and Vice President, Clinical Sciences for Cardiac Rhythm Management Group
Devices Cardiology Personnel
 HSMN NewsFeed - 20 Oct 2006
FDA Approves Prescription Zaditor(R) for Over-The-Counter Relief From Itchy Eyes
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2006
Novartis Launches 'GALIANT' Study Comparing the Investigational Drug Galvus(R) and a Leading Class of Oral Anti-Diabetic Medicines
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 5 Oct 2006
Tracy Lawhon, J.D., Joins Cabrellis Pharmaceuticals as Vice President, Regulatory Affairs and Development Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Oct 2006
Genentech Announces Vice President Appointments in Commercial Operations and Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2006
Regeneron Names Peter Powchik, M.D., Senior Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Sep 2006
TAP Enters Into Co-Promotion Agreement for Famvir(R)
Biopharmaceuticals
 HSMN NewsFeed - 28 Sep 2006
New Data for FTY720 -- Aiming to Become the First Orally Effective Multiple Sclerosis Treatment -- Show Sustained Benefits Over Two Years
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Sep 2006
ZIOPHARM Appoints John Amedio, Ph.D. as Vice President, Manufacturing & Process Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Sep 2006
Once-Yearly Reclast(R)* Demonstrates Highly Significant Fracture Risk Reductions in the Treatment of Postmenopausal Osteoporosis, New Study Shows
Biopharmaceuticals
 HSMN NewsFeed - 14 Sep 2006
Sara Zaknoen, M.D., Joins Cabrellis Pharmaceuticals as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Sep 2006
FibroGen Appoints Melissa L. Grigorieff, Vice President of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Aug 2006
Genaera Appoints Anthony DelConte, MD, as Vice President of Clinical Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Aug 2006
Portola Announces the Appointment of Mardi Dier to Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Aug 2006
inVentiv Health Announces New Sales Team Agreement With Novartis Pharmaceuticals
Biopharmaceuticals
 HSMN NewsFeed - 28 Jul 2006
FDA Approves Supplemental New Drug Application for Antiviral Treatment Famvir(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jul 2006
Genzyme Launches New Diagnostic Test for Common Blood Cancer
Diagnositcs Oncology
 HSMN NewsFeed - 26 Jul 2006
Phase III Study Demonstrates Once-a-Day Prograf MR(TM) (Modified Release) and Twice-Daily Prograf(R) Are as Effective as Neoral(R) in Kidney Transplant Recipients
Biopharmaceuticals
 HSMN NewsFeed - 26 Jul 2006
After Conversion to myfortic(R), Two-Thirds of Renal Transplant Recipients With Gastrointestinal Problems and Their Physicians Report a Significant Overall Reduction in Gastrointestinal Symptom Burden
Biopharmaceuticals
 HSMN NewsFeed - 19 Jul 2006
Exelon(R) Patch, the first transdermal therapy for Alzheimer's disease, may provide a promising new approach to treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Jun 2006
The U.S. Food and Drug Administration Approves Exelon(R) (rivastigmine tartrate) as the First Medication Indicated to Treat Parkinson's Disease Dementia
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 14 Jun 2006
Patients With Treatment-Resistant Leukemia Achieve High Responses to Tasigna(R) (nilotinib) in First Published Clinical Trial Results
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2006
Novartis Unveils Further Impressive Efficacy Data for Galvus(R), an Investigational Oral Diabetes Compound, Showing Significant Blood Sugar Reductions
Biopharmacetuicals Endocrinology
 HSMN NewsFeed - 9 Jun 2006
FDA Approves New Lotrel(R) 5/40 mg and 10/40 mg Dosage Strengths
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jun 2006
Gleevec(R) Sets New Treatment Standard in Chronic Myeloid Leukemia With High Overall Survival, Increasing Response and Decreasing Progression
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2006
New Data Show Overactive Bladder Therapy Enablex(R) Does Not Impair Memory Function Compared to Frequently Used Alternative
Biopharmaceuticals Urology Neurology
 HSMN NewsFeed - 22 May 2006
Study Reveals Zelnorm(R) May Be a Safe and Effective Treatment for Additional Group of IBS Patients With a Mixed Bowel Pattern
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2006
ProEthic Pharmaceuticals Initiates Pivotal Phase III Trial for Fast-Acting Migraine Product Candidate
Biopharmaceuticals
 HSMN NewsFeed - 19 May 2006
Biovail to Promote Novartis' Lescol(R) Franchise in Canada; Lescol(R) Provides Treatment Option for Patients Who Need a Statin to Reduce Cardiovascular Risk
Biopharmaceuticals
 HSMN NewsFeed - 19 May 2006
Diovan(R) (valsartan) the First Blood Pressure Medication in a Large-Scale Clinical Trial to Lower C-Reactive Protein, an Important Marker of Inflammation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 17 May 2006
FDA Advisory Committee Recommends Approval of Exelon(R) (rivastigmine tartrate) in the Treatment of Dementia Associated with Parkinson's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 May 2006
Novartis Announces Efficacy Data on New Investigational High Blood Pressure Therapies at The American Society of Hypertension Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 15 May 2006
Novo Nordisk Announces New Key Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2006
Axcan Pharma appoints new Senior Vice President and Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2006
Novo Nordisk Appoints Edward Williams as Vice President of Biopharmaceuticals
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2006
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 May 2006
FDA Approves Higher Dose Formulations of Diovan HCT(R) (valsartan/hydrochlorothiazide) for Treatment of High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Apr 2006
US Submission of Exforge(R) Accepted for Review by the FDA as a New Therapy Option for High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Apr 2006
New Drug Application (NDA) for Rasilez(R) (Aliskiren), an Innovative Oral Renin Inhibitor to Treat High Blood Pressure, Accepted for Review by the US FDA
Biopharmaceuticals
 HSMN NewsFeed - 18 Apr 2006
Novadaq hires Vice President and General Manager of Ophthalmology
Devices Ophthalmology Personnel
 HSMN NewsFeed - 11 Apr 2006
Biophan Technologies, Inc. Announces Appointment of Daniel G. Hullihen as Director of Business Development
Devices Personnel
 HSMN NewsFeed - 10 Apr 2006
Novartis completes submissions in US and Europe for Gleevec(R) as treatment for four rare types of cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Apr 2006
Noven Announces FDA Approval of Daytrana(TM) Methylphenidate Transdermal System
Biopharmaceuticals FDA Drug Delivery
 HSMN NewsFeed - 4 Apr 2006
Protalex Organizational Announcement
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Mar 2006
New drug application for Galvus(R), an innovative oral therapy for people with type 2 diabetes, accepted for review by FDA
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 27 Mar 2006
New Data Shows Telbivudine Provided Significantly Greater Response Compared to Lamivudine in the Treatment of Chinese Patients with Chronic Hepatitis B
Biopharmaceuticals
 HSMN NewsFeed - 13 Feb 2006
American Pharmaceutical Partners Receives Two FDA Approvals for Octreotide Acetate Injection
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 24 Jan 2006
Noven Provides Update on Vivelle-Dot(TM) Estrogen Patch
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 23 Jan 2006
Idenix Pharmaceuticals, Inc. Announces Appointment of Susan Koppy as Senior Vice President, Business and Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jan 2006
Columbia Laboratories Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jan 2006
NitroMed Promotes Michael Sabolinski, M.D. to the Position of Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2006
Idenix and Novartis Announce New Drug Application Submitted to the U.S. Food and Drug Administration for Telbivudine for The Treatment of Chronic Hepatitis B
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 121

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 121 additional stories matching:
Novartis Pharmaceuticals
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.